Royalty Pharma plc (RPRX)

60.85 -1.73% (-1.07)

Over 5Y: +75.0%

2026-08-28
40 60
2021 2022 2023 2024 2025 2026

Financials Quarterly

Q3 '25 — Revenue: 609.3M Q3 '25 — Operating Cash Flow: 702.6M Q3 '25 — Net Income: 288.2M Q4 '25 — Revenue: 622M Q4 '25 — Operating Cash Flow: 827.1M Q4 '25 — Net Income: 214.2M Q1 '26 — Revenue: 630.6M Q1 '26 — Operating Cash Flow: 718.2M Q1 '26 — Net Income: 294.7M Q2 '26 — Revenue: 674.1M Q2 '26 — Operating Cash Flow: 728.5M Q2 '26 — Net Income: 17.9M 0 200M 400M 600M 800M 1B
Q3 '25 Q4 '25 Q1 '26 Q2 '26
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

6.6
OE margin 100.5%
Oper. margin 59.6%
SBC / sales 16.9%
ROIC 6.5%
Accruals -10.9%
FCF margin 117.4%
OCF / EBIT 2.0×
OCF margin 117.4%
ROA 4.1%
ROCE 7.9%
ROE 8.3%
Capex / sales —
Gross margin —

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

3.5
RPO / sales —
RPO growth —
Segment HHI —

2 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

4.6
ND/EBITDA —
Payout 0.0%
Quick ratio 2.8×
Debt payback 2.9 yr
Debt / Eq 0.95×
F-score 5.6 pts
Net debt / Eq 0.87×
Cash / Debt 0.09×
Cash runway —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

3.8
Sales/sh Y/Y +15.8%
Sales CAGR 4Y +0.96%
EBIT CAGR +57.8%
Sales Q/Q +16.5%
EPS Y/Y -16.2%
EBIT Y/Y -17.9%
Div. growth —
EPS CAGR 4Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.